FundingWatcher
Home / Startups / By venture fund / Forbion Capital Partners portfolio companies

Forbion Capital Partners portfolio companies

Updated 16 Nov 2026

http://www.forbion.com

Forbion Capital Partners portfolio companies
One-time CSV
  • 25 funded companies, 24 with a website
  • Last round, amount, date, total raised and investors
  • CRM-ready CSV, 18 columns
  • Download right after payment
With founder contacts
Compiled to order
  • The full startup CSV, plus founders and executives
  • Up to 2 founders or CEOs per company, compiled to order
  • Name, job title and LinkedIn URL where found
  • Verified direct email per person
  • Startup CSV at once, contacts CSV by mail within 24 hours
Download right after paymentFree 10-row sampleSecure checkout by Stripe

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

startups-investor-forbion-capital-partners.csv25 rows × 18 columns
CompanyCityLast roundAmountDate
Seamless TherapeuticsDresdenSeed$12.6M2024-04-23
KynexisNaardenSeries A$112.3M2026-08-19
Beacon TherapeuticsAlachuaSeries C$75.0M2026-01-08
AIRNACambridgeSeries B$155.0M2025-04-01
Marea TherapeuticsSan FranciscoSeries B$190.0M2024-06-18
SynOx TherapeuticsDublinSeries B$92.0M2024-10-30
VectorYAmsterdamSeries A$138.0M2023-11-13
Calluna PharmaOsloSeries A$81.4M2024-01-23

8 rows of the CSV in 5 of its 18 columns.

25
Startups
$3.3B
Total raised
2
Funded in the last 12 months
$187.3M
Raised in the last 12 months

Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.

Newest rounds

14 of 25
14 rows
Company What they do Sector Location Last round Amount Date Total raised Investors Employees Founded
Kynexis Kynexis develops precision medicine treatments for cognitive impairment associated with schizophrenia. Biotech Naarden, The Netherlands Series A $112.3M 2026-08-19 $173.3M Forbion Capital Partners, Ysios Capital, Sunstone Life Science Ventures 11 to 50 2023
Beacon Therapeutics Beacon Therapeutics develops treatments to preserve and restore vision for eye diseases. Biotech Alachua, United States Series C $75.0M 2026-01-08 $365.1M Oxford Science Enterprises, Forbion Capital Partners, Advent Life Sciences +1 101 to 250 2023
AIRNA AIRNA develops RNA editing technologies to create medicines for various diseases. Biotech Cambridge, United States Series B $155.0M 2025-04-01 $245.0M ARCH Venture Partners, Alexandria Venture Investments, Forbion Capital Partners +2 51 to 100 2021
Noema Pharma Noema Pharma develops therapies that treat disabling symptoms of brain and nervous system conditions. Biotech Basel, Switzerland Series B $147.2M 2024-12-11 $316.5M Polaris Partners, Sofinnova Partners, Invus +2 11 to 50 2019
SynOx Therapeutics SynOx Therapeutics is a biotechnology company developing treatments for diffuse tenosynovial giant cell tumors. Biotech Dublin, Ireland Series B $92.0M 2024-10-30 $245.9M Forbion Capital Partners, Gimv, Hercules Capital +2 1 to 10 2020
Solasta Bio Solasta Bio develops environmentally friendly crop protection products. Biotech Glasgow, United Kingdom Series A $14.0M 2024-09-11 Scottish Enterprise, Future Planet Capital, Forbion Capital Partners 11 to 50 2020
CatalYm CatalYm develops immunotherapies to treat cancer. Biotech Planegg, Germany Series D $150.0M 2024-07-16 $260.9M Bayern Kapital, Forbion Capital Partners, Novartis Venture Fund +1 11 to 50 2016
Progentos Therapeutics Progentos Therapeutics develops a multiple sclerosis treatment that stimulates the body's natural repair mechanisms. Biotech Watertown, United States Series A $65.0M 2024-05-14 $65.0M Forbion Capital Partners, Dolby Family Ventures, Alta Partners +2 11 to 50 2023
Calluna Pharma Calluna Pharma develops first-in-class therapies that target chronic inflammation and fibrosis at their source. Biotech Oslo, Norway Series A $81.4M 2024-01-23 Forbion Capital Partners, Investinor, Sarsia +1 11 to 50 2024
VectorY VectorY develops gene therapies for central nervous system, somatic, and muscle diseases. Biotech Amsterdam, The Netherlands Series A $138.0M 2023-11-13 $175.6M Insight Partners, Benhamou Global Ventures, Forbion Capital Partners +2 51 to 100 2020
Aiolos Bio Aiolos Bio is a biotech company developing therapies for respiratory diseases and immune conditions. Biotech San Francisco, United States Series A $245.0M 2023-10-24 $245.0M RA Capital Management, Atlas Venture, Forbion Capital Partners +2 11 to 50 2023
Rampart Bioscience Rampart Bioscience develops gene medicines for long-lasting treatment of diverse diseases. Biotech La Jolla, United States Series A $85.0M 2023-10-24 $85.0M RA Capital Management, OrbiMed, Forbion Capital Partners +1 11 to 50 2019
Mariana Oncology Mariana Oncology conducts biotechnology research in the oncology field. Biotech Watertown, United States Series B $175.0M 2023-09-07 $250.0M RA Capital Management, Forbion Capital Partners, Surveyor Capital +1 11 to 50 2021
Roche Glycart Roche Glycart researches, develops, and commercializes antibody-based biotechnology products. Biotech Schlieren, Switzerland Series A $13.6M 2003-11-26 $13.6M Forbion Capital Partners, Novartis Venture Fund, BioMedPartners +1 101 to 250 2000

Table 1. Forbion Capital Partners portfolio companies: the 14 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 25.

Largest rounds

Last 12 months
# Company What they do Sector Location Last round Amount Date Total raised Investors Employees Founded
1 Kynexis Kynexis develops precision medicine treatments for cognitive impairment associated with schizophrenia. Biotech Naarden, The Netherlands Series A $112.3M 2026-08-19 $173.3M Forbion Capital Partners, Ysios Capital, Sunstone Life Science Ventures 11 to 50 2023
2 Beacon Therapeutics Beacon Therapeutics develops treatments to preserve and restore vision for eye diseases. Biotech Alachua, United States Series C $75.0M 2026-01-08 $365.1M Oxford Science Enterprises, Forbion Capital Partners, Advent Life Sciences +1 101 to 250 2023

Table 2. Forbion Capital Partners portfolio companies: the 2 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most active investors

By companies backed
#InvestorTypeLocation CompaniesShare Funded, 12 monthsLatest
1 RA Capital Management Startup incubator Boston, United States 3 12%
2 Novartis Venture Fund Corporate venture arm Basel, Switzerland 3 12%
3 Perceptive Advisors Hedge fund New York, United States 2 8%
4 Surveyor Capital Hedge fund Chicago, United States 2 8%
5 Bioqube Ventures Venture capital firm Hasselt, Belgium 2 8%
6 Sofinnova Partners Venture capital firm Paris, France 2 8%
7 ABN AMRO Fund Corporate venture arm Amsterdam, The Netherlands 2 8%
8 Gilde Healthcare Private equity firm Utrecht, The Netherlands 2 8%
9 GO-Bio Government investment office Berlin, Germany 1 4%
10 Wellington Partners Venture capital firm Munich, Germany 1 4%
11 Sunstone Life Science Ventures Micro VC fund Copenhagen, Denmark 1 4% 1 Kynexis
12 Ysios Capital Venture capital firm San Sebastian, Spain 1 4% 1 Kynexis
13 TCG Crossover Hedge fund Palo Alto, United States 1 4% 1 Beacon Therapeutics
14 Advent Life Sciences Venture capital firm London, United Kingdom 1 4% 1 Beacon Therapeutics
15 Oxford Science Enterprises Venture capital firm Oxford, United Kingdom 1 4% 1 Beacon Therapeutics

Table 3. Forbion Capital Partners portfolio companies: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Sectors

SectorsCompaniesShareTotal raised
Biotech 23 92% $3.2B
Health care 22 88% $3.0B
Software 2 8% $68.3M

Table 4. Forbion Capital Partners portfolio companies by sector. Source: FundingWatcher. Data as of 16 November 2026.

Funding stage

Funding stageCompaniesShareMedian last round
Seed 2 8% $12.6M
Series A 9 36% $81.4M
Series B 11 44% $120.0M
Series C 1 4% $75.0M
Series D+ 2 8% $150.0M

Table 5. Forbion Capital Partners portfolio companies by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Countries

CountriesCompaniesShare
United States 9 36%
Germany 4 16%
United Kingdom 4 16%
The Netherlands 3 12%
Switzerland 2 8%
Ireland 1 4%
Norway 1 4%
Spain 1 4%

Table 6. Forbion Capital Partners portfolio companies by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.

Cities

CitiesCompaniesShare
Naarden 2 8%
San Francisco 2 8%
Watertown 2 8%
Dresden 1 4%
Alachua 1 4%
Cambridge 1 4%
Dublin 1 4%
Amsterdam 1 4%
Oslo 1 4%
La Jolla 1 4%
Basel 1 4%
Tarrytown 1 4%

Table 7. Forbion Capital Partners portfolio companies by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.

Rounds by month

Rounds by monthCompaniesShareRaised
August 2026 1 50% $112.3M
January 2026 1 50% $75.0M

Table 8. Forbion Capital Partners portfolio companies: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most recent round by year

Most recent round by yearCompaniesShareRaised
2026 2 8% $187.3M
2025 1 4% $155.0M
2024 12 48% $1.1B
2023 5 20% $651.5M
2021 1 4% $35.0M
2016 1 4% $24.8M

Table 9. Forbion Capital Partners portfolio companies by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Founding year

Founding yearCompaniesShare
2023 or later 5 20%
2020 to 2022 9 36%
2015 to 2019 5 20%
2010 to 2014 2 8%
Before 2010 4 16%

Table 10. Forbion Capital Partners portfolio companies by founding year. Source: FundingWatcher. Data as of 16 November 2026.

Team size

Team sizeCompaniesShare
1 to 10 3 12%
11 to 50 17 68%
51 to 100 2 8%
101 to 250 3 12%

Table 11. Forbion Capital Partners portfolio companies by headcount. Source: FundingWatcher. Data as of 16 November 2026.

Method

Sources, fields and exclusions of both files: Method.

Questions

How many Forbion Capital Partners portfolio companies are on the list?
25, in the file dated 16 November 2026. 2 of them closed their most recent round in the last 12 months.
What does the CSV contain?
One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
How much does the list cost?
$29 one-time for all 25 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
What arrives after payment?
At once: the CSV download link, on the page after payment and by mail.
Can I see rows before buying?
The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
How current is the data?
The file is dated 16 November 2026. The download link serves the current file each time it is opened.

Forbion Capital Partners portfolio companies: 25 rows, CSV, $29 one-time.

At once: the CSV download link, on the page after payment and by mail.

Columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.

With founder contacts: $199 one-time. List CSV right after payment; up to 2 verified founder or CEO emails per company compiled to order within 24 hours.

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

Portfolio companies by country

Portfolio companies by city

Other venture fund portfolios

Cite: FundingWatcher, 25 startups, 16 November 2026. https://fundingwatcher.com/startups/investor/forbion-capital-partners/